特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
838360

鎌状赤血球症 (SCD) 治療の世界市場:産業分析・市場規模・市場シェア・成長率・市場動向・予測

Global Sickle Cell Disease Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends And Forecast 2018 to 2025

出版日: | 発行: Value Market Research | ページ情報: 英文 | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=106.41円
鎌状赤血球症 (SCD) 治療の世界市場:産業分析・市場規模・市場シェア・成長率・市場動向・予測
出版日: 2019年03月01日
発行: Value Market Research
ページ情報: 英文
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界の鎌状赤血球症 (SCD) 治療市場を調査し、市場の定義と概要、バリューチェーン、市場成長への各種影響因子および市場機会の分析、治療法・地域別の動向と市場規模の推移と予測、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場分析

  • イントロダクション
  • バリューチェーン分析
  • 成長推進因子
  • 成長抑制因子
  • 市場機会
  • ポーターのファイブフォース分析

第4章 鎌状赤血球症 (SCD) 治療市場の分析:タイプ別

  • ワクチン・抗体による感染予防市場
  • 輸血市場
  • ヒドロキシカルバミド治療薬市場
  • 骨髄細胞の移植

第5章 鎌状赤血球症 (SCD) 治療市場の分析:用途別

  • 病院
  • ASC (通院外科診療所)
  • 診療所
  • その他

第6章 鎌状赤血球症 (SCD) 治療市場の分析:地域別

  • 北米
  • 欧州 (EU)
  • アジア太平洋
  • ラテンアメリカ
  • 中東・アフリカ (MEA)

第7章 競合環境

  • 市場競合
  • 提携・協力・合意
  • M&A
  • 新製品の開発
  • その他

第8章 企業プロファイル

  • Acceleron Pharma
  • Alnylam Pharmaceuticals
  • Arena Pharmaceuticals
  • AstraZeneca
  • Baxter
  • Bluebird Bio
  • Bristol-Myers Squibb
  • Eli Lilly
  • Emmaus Life Sciences
  • Global Blood Therapeutics Novartis
  • Pfizer
  • Sangamo Therapeutics
  • Tentative TOC
目次

The report on Global Sickle Cell Disease Treatment Market evaluates the growth trends of the industry through historical study and estimates future prospects based on comprehensive research. The report extensively provides the market share, growth, trends and forecasts for the period 2018-2025. The market size in terms of revenue (USD MN) is calculated for the study period along with the details of the factors affecting the market growth (drivers and restraints).

  • Drivers
    • Growing patient pool and high unmet medical needs
    • Increasing investment by the government in order to improve the healthcare services
  • Restraints
    • High cost of treatment and unavailability of required drugs

Furthermore, the report quantifies the market share held by the major players of the industry and provides an in-depth view of the competitive landscape. This market is classified into different segments with detailed analysis of each with respect to geography for the study period:

  • Base Year: 2018
  • Estimated Year: 2019
  • Forecast Till: 2025

The comprehensive value chain analysis of the market will assist in attaining better product differentiation, along with detailed understanding of the core competency of each activity involved. The market attractiveness analysis provided in the report aptly measures the potential value of the market providing business strategists with the latest growth opportunities.

The report classifies the market into different segments based on type and application. These segments are studied in detail incorporating the market estimates and forecasts at regional and country level. The segment analysis is useful in understanding the growth areas and probable opportunities of the market.

The report also covers the complete competitive landscape of the worldwide market with company profiles of key players such as Acceleron Pharma, Alnylam Pharmaceuticals, Arena Pharmaceuticals, AstraZeneca, Baxter, Bluebird Bio, Bristol-Myers Squibb, Eli Lilly, Emmaus Life Sciences, Global Blood Therapeutics Novartis, Pfizer, Sangamo Therapeutics. A detailed description of each has been included, with information in terms of H.Q, future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other latest industrial developments.

SEGMENTATIONS IN THE REPORT:

By Type:

  • Infection Prevention with Vaccination and Antibiotics
  • Blood Transfusion
  • The Medication Hydroxycarbamide
  • A Transplant of Bone Marrow Cells

By Applications:

  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
  • Others

By Geography:

  • North America (NA) - US, Canada & Rest of North America
  • Europe (EU) - UK, Germany, France & Rest of Europe
  • Asia Pacific (APAC) - China, Japan, India & Rest of APAC
  • Latin America (LA) - Brazil & Rest of Latin America
  • Middle East & Africa (MEA) - Middle East and Africa

Table of Contents

1. INTRODUCTION

  • Report Description
  • Research Scope
  • Research Methodology

2. EXECUTIVE SUMMARY

  • Market Highlight
  • Global Sickle cell disease treatment Market: Snapshot

3. MARKET ANALYSIS

  • Introduction
  • Value Chain Analysis
  • Drivers
  • Restraints
  • Opportunities
  • Porter's Five Forces Analysis

4. SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS BY TYPES

  • Market In Infection Prevention with Vaccination and Antibiotics
  • Market In Blood Transfusion
  • Market In The Medication Hydroxycarbamide
  • Market In A Transplant of Bone Marrow Cells

5. SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS BY APPLICATION

  • Market In Hospitals
  • Market In Ambulatory Surgical Centers
  • Market In Clinics
  • Market In Others

6. SICKLE CELL DISEASE TREATMENT MARKET ANALYSIS BY GEOGRAPHY

  • North America (NA)
  • North America Market Estimates
  • North America Market Estimates By Country
  • United States (U.S.)
  • Canada
  • Rest Of North America
  • Europe (EU)
  • Europe Market Estimates
  • Europe Market Estimates By Country
  • United Kingdom (UK)
  • Germany
  • France
  • Rest Of Europe
  • Asia Pacific (APAC)
  • Asia Pacific Market Estimates
  • Asia Pacific Market Estimates By Country
  • China
  • Japan
  • India
  • Rest Of Asia Pacific
  • Latin America (LA)
  • Latin America Market Estimates
  • Latin America Market Estimates By Country
  • Brazil
  • Rest Of Latin America
  • Middle East And Africa (MEA)
  • Middle East And Africa Market Estimates
  • Middle East And Africa Market Estimates By Country
  • Middle East
  • Africa

7. COMPETITIVE LANDSCAPE OF THE SICKLE CELL DISEASE TREATMENT COMPANIES

  • Market Competition
  • Partnerships/Collaborations/Agreements
  • Mergers And Acquisitions
  • New Product Launches
  • Other Developments

8. COMPANY PROFILES OF THE SICKLE CELL DISEASE TREATMENT INDUSTRY (Company Overview, Financial, Major Products & Recent Development)

  • Acceleron Pharma
  • Alnylam Pharmaceuticals
  • Arena Pharmaceuticals
  • AstraZeneca
  • Baxter
  • Bluebird Bio
  • Bristol-Myers Squibb
  • Eli Lilly
  • Emmaus Life Sciences
  • Global Blood Therapeutics Novartis
  • Pfizer
  • Sangamo Therapeutics
  • Tentative TOC
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.